L1CAM Predicts Adverse Outcomes in Patients with Endometrial Cancer Undergoing Full Lymphadenectomy and Adjuvant Chemotherapy-Reference-Cited by-同舟云学术

L1CAM Predicts Adverse Outcomes in Patients with Endometrial Cancer Undergoing Full Lymphadenectomy and Adjuvant Chemotherapy

Published:2019-12-02 Issue:7 Volume:27 Page:2159-2168
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Asano Hiroshi,Hatanaka Kanako C.,Matsuoka Ryosuke,Dong Peixin,Mitamura Takashi,Konno Yosuke,Kato Tatsuya,Kobayashi Noriko,Ihira Kei,Nozaki Ayako,Oku Akira,Matsuno Yoshihiro,Hatanaka Yutaka,Watari Hidemichi

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-019-08103-2.pdf

Reference28 articles.

1. Kiefel H, Bondong S, Hazin J, et al. L1CAM: a major driver for tumor cell invasion and motility. Cell Adh Migr. 2012;6(4):374–84.

2. Cancer Genome Atlas Research N, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.

3. Stelloo E, Nout RA, Osse EM, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res. 2016;22(16):4215–24.

4. Zeimet AG, Reimer D, Huszar M, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst. 2013;105(15):1142–50.

5. Fogel M, Gutwein P, Mechtersheimer S, et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003;362(9387):869–75.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How Can “No Specific Molecular Profile” Heterogeneity be Reduced in Molecularly Classified Endometrial Cancer?: Prognostic Significance of L1 Cell Adhesion Molecule;International Journal of Gynecological Pathology;2024-07-29

2. The tumour‐derived extracellular vesicle proteome varies by endometrial cancer histology and is confounded by an obesogenic environment;PROTEOMICS;2024-04-21

3. A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer;Nature Communications;2024-01-22

4. Enhanced Risk Stratification in Early-Stage Endometrial Cancer: Integrating POLE through Droplet Digital PCR and L1CAM;Cancers;2023-10-09

5. Mesonephric-like Adenocarcinoma of the Uterine Corpus: Clinicopathological and Prognostic Significance of L1 Cell Adhesion Molecule (L1CAM) Over-expression;Anticancer Research;2023-09-29